Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer. - Wikidata - awgldk - TriplyDB

Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.

Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.

http://www.wikidata.org/entity/Q37507842

about

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity.

P2860

Q33416440-D95FD425-7F88-4B96-B985-8CAB613EB8B9 Q37322979-CA923C13-BBC5-45AA-AE5E-7C6D4D9B8022

P2860

Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.

http://www.wikidata.org/entity/Q37507842

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evaluation of pegylated liposo ...... recurrent endometrial cancer.

@en

Evaluation of pegylated liposo ...... recurrent endometrial cancer.

@nl

type

label

Evaluation of pegylated liposo ...... recurrent endometrial cancer.

@en

Evaluation of pegylated liposo ...... recurrent endometrial cancer.

@nl

prefLabel

Evaluation of pegylated liposo ...... recurrent endometrial cancer.

@en

Evaluation of pegylated liposo ...... recurrent endometrial cancer.

@nl

P1433

Q37507842-5191EDEE-0DF2-446B-8B70-52700BFCE26D

P1476

Q37507842-18100623-4352-4F4E-9F5E-DAA6862F41B0

P2093

Q37507842-2A4A8337-8544-4912-9F16-B0210DA54A04

Q37507842-32EF33DF-B7B0-497B-94F0-D59C7B710F4A

Q37507842-72E851E7-82A6-4417-8F91-E4503BA2C58E

Q37507842-B7A4000D-B798-491D-8E0A-E28ED37431FD

Q37507842-D17782F8-5647-46A3-940F-6F8454F661E3

Q37507842-F34770ED-C7ED-405D-8D69-2E981FE3261C

Q37507842-FF7942D5-2168-4EF1-BDC2-B74061C72BC7

P2860

Q37507842-02F58536-B4F7-4824-A48E-C2ACCD0DDD53

Q37507842-0F6D0E06-89B9-482C-90DC-2AF3D665CDFF

Q37507842-0FAB3184-8A23-4C59-88D5-5D499E3F5B40

Q37507842-10ECA0EB-5F06-4331-8277-CA77699E7F4C

Q37507842-137E107A-FC22-4006-ADDC-C31D6E50F3EE

Q37507842-26526B33-481A-49B3-A32A-6C0DF5B682CD

Q37507842-315156D0-C6B1-4BC1-8504-38E84F3B11C1

Q37507842-4BD2768F-6B97-48E9-A869-E601C6382FB5

Q37507842-86488B72-97F1-4635-B5F8-CE1D9E553504

Q37507842-8801A05E-7CED-441D-B09A-C70CBE59017B

P304

Q37507842-20AF9058-9FC1-4593-A71C-65FB8B4C3CFE

P31

Q37507842-8D3D7BED-F91F-47DB-8718-00E9EF46268B

P356

Q37507842-9D75D673-0273-4DF4-A0C6-0EFCC4B595C0

P433

Q37507842-5099AA99-AA27-45D8-93C5-EB1469A4660F

P478

Q37507842-51367D04-5846-4CBA-8B0D-6C599FB07241

P577

Q37507842-D6810440-B347-4F85-B12C-0D243558FF93

P698

Q37507842-1BCD5FA6-DCE3-444B-A001-C709C173B2AF

P932

Q37507842-5520E3AF-24BE-45B1-BC46-0C04E838ADBF

P356

IGC.0B013E31827C18F3

P1433

International Journal of Gynecological Cancer

P1476

Evaluation of pegylated liposo ...... recurrent endometrial cancer.

@en

P2093

Graciela M Nogueras-Gonzalez

http://www.w3.org/2001/XMLSchema#string

Jack L Watkins

http://www.w3.org/2001/XMLSchema#string

Janos L Tanyi

http://www.w3.org/2001/XMLSchema#string

Judith A Smith

http://www.w3.org/2001/XMLSchema#string

Judith K Wolf

http://www.w3.org/2001/XMLSchema#string

Justin M Julius

http://www.w3.org/2001/XMLSchema#string

Robert L Coleman

http://www.w3.org/2001/XMLSchema#string

P2860

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.

Phase II study of liposomal doxorubicin in advanced gynecologic cancers.

Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.

The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.

Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.

Role of pegylated liposomal doxorubicin in ovarian cancer.

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.

P304

348-354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/IGC.0B013E31827C18F3

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23295941

http://www.w3.org/2001/XMLSchema#string

P932

3899886

http://www.w3.org/2001/XMLSchema#string